As of 2024-12-15, the Fair Value of Newbury Pharmaceuticals AB (NEWBRY.ST) is -4.51 SEK. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 3.60 SEK, the upside of Newbury Pharmaceuticals AB is -225.36%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-08-31 | 2022-08-31 | 2023-08-31 | - | - | 5Y Avg | |
| Net income | -14.67 | -19.43 | - | - | -17.05 | |
| YoY growth | -163.96% | -32.48% | - | - | -98.22% | |
| Market Cap (mil) | 87.34 |
| P/E | |
| Forward P/E |
| EPS | -0.90 |
| Avg earnings growth rate | -98.22% |
| TTM earnings | -21.90 |